David Glassman, MD
Interventional Pain Medicine · New Haven, CTNPI 1831127265
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $2,056 of the $2,860 with a category attached, or 71.9%. 11 manufacturers reported payments, led by Medtronic at 35.7% of the total. 2025 is the largest year on record at $827, 2.7 times the $307 reported in 2019.
Across 72 payments — averaging $39.73 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Medtronic$1K
- Globus Medical$805
- Merck$375
- Vertos Medical, Inc.$185
- AbbVie$177
- Bioventus LLC$176
- plus $122 from 5 others
What the payments were for
- Travel & lodging$80528%
- Food & beverage$2,05672%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Medtronic(2 entities) | 28 | $1,022 |
| Globus Medical | 5 | $805 |
| Merck | 19 | $375 |
| Vertos Medical, Inc. | 4 | $185 |
| AbbVie(2 entities) | 7 | $177 |
| Bioventus LLC | 4 | $176 |
| Stryker | 1 | $46 |
| Bayer | 1 | $22 |
| Heron Therapeutics, Inc. | 1 | $21 |
| Endo Pharmaceuticals Inc. | 1 | $19 |
| Amgen | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Excelsius - GPS$620
- AUTOFILL$142
- INTELLIS ADAPTIVESTIM$141
How this compares
Too few interventional pain medicine providers in Connecticutto place this figure against a meaningful peer group, so we don't.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Gabapentin | 32 | $529 |
| Ibuprofen | 39 | $470 |
| Baclofen | 42 | $463 |
| Celecoxib | 26 | $288 |
| Tizanidine Hcl | 14 | $248 |
| Clonazepam | 12 | $143 |
| Pregabalin | 16 | $79 |
| Methylprednisolone | 13 | $75 |
| Meloxicam | 12 | $25 |
Paid to pharmacies, not to this prescriber.
Other interventional pain medicine in New Haven
- Dwight LighamNew Haven$7K
- Richard LucarelliVernon$71K
- Mohan VodapallyHamden$26K
- Mark ThimineurDerby$17K
- Robert BoolbolFarmington$15K
- Shyam DesaiFairfield$14K
- Michael GrilleHartford$10K
- Jonathan KostWest Hartford$10K
- Pardeep SoodTrumbull$8K
- Vincent CarlesiDanbury$8K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.